FIA
CLRB icon

FNY Investment Advisers’s Cellectar Biosciences CLRB Stock Holding History

FNY Investment Advisers’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-734
Closed -$262K – 732
2021
Q2 		$262K Hold
734
– – 0.1% 161
2021
Q1 		$354K Hold
734
– – 0.13% 129
2020
Q4 		$458K Buy
734
+56
+8% +$25.7K 0.12% 140
2020
Q3 		$252K Buy
678
+250
+58% +$98.8K 0.11% 149
2020
Q2 		$164K Buy
428
+196
+84% +$82.3K 0.1% 138
2020
Q1 		$88K Buy
+232
New +$155K 0.07% 185

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FNY Investment Advisers's CLRB Position: Q3 2021 in Review

FNY Investment Advisers sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 734 shares — an estimated $262K sold.

FNY Investment Advisers first reported a position in CLRB in Q1 2020 and held it in 6 quarters. The position peaked at $458K in Q4 2020. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

  • FNY Investment Advisers reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
  • FNY Investment Advisers sold 734 Cellectar Biosciences shares in Q3 2021, an estimated $262K.
  • FNY Investment Advisers first reported a position in Cellectar Biosciences in Q1 2020 and held it in 6 quarters.
  • FNY Investment Advisers's Cellectar Biosciences position peaked at $458K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on FNY Investment Advisers's 13F filing for Q3 2021, filed 13 Oct 2021.